SLC5A2 and heart failure: The use of SGLT-2 inhibitors such as empagliflozin for the treatment of heart failure patients has been shown to be associated with elevated serum asprosin levels, suggesting that asprosin may account, at least in part, for the beneficial effects of these drugs [189].